Siren Biotechnology, a startup focused on reimagining cancer treatment, has closed an $8.0M Series A funding round. The company is developing a Universal AAV Immuno-Gene Therapy, a novel modality that merges two transformative therapeutic technologies: AAV gene therapy and cytokine immunotherapy. This combined approach aims to overcome key challenges in oncology, redefining how tumor cells are destroyed and how anti-tumor immunity is elicited.















.png&w=3840&q=75)


